Fentiazac

Template:Short description Template:Short description Template:Template other{{Infobox drug/maintenance categoriesTemplate:Yesno | drug_name = | INN = | _drugtype =

| _has_physiological_data= | _has_gene_therapy=

| vaccine_type= | mab_type= | _number_of_combo_chemicals= | _vaccine_data= | _mab_data= | _mab_vaccine_data= | _mab_other_data=171212c1ccc(cc1)c2nc(c(s2)CC(=O)O)c3ccc(cc3)Cl1S/C17H12ClNO2S/c18-13-8-6-11(7-9-13)16-14(10-15(20)21)22-17(19-16)12-4-2-1-3-5-12/h1-9H,10H2,(H,20,21)JIEKMACRVQTPRC-UHFFFAOYSA-NTemplate:StdinchiciteTemplate:Stdinchicite162-163 | _combo_data= | _physiological_data= | _clinical_data=Template:Drugs.com NorvedanM02 | _legal_data=

| _other_data=2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid

| _image_0_or_2 = fentiazac.pngFentiazac-3D-balls.png | _image_LR =

| _datapage = Fentiazac (data page) | _vaccine_target=_type_not_vaccine | _legal_all= | _ATC_prefix_supplemental=M02 | _has_EMA_link = | CAS_number=18046-21-4 | PubChem=28871 | ChemSpiderID=26854 | ChEBI= | ChEMBL=589092 | DrugBank= | KEGG=D01975 | _hasInChI_or_Key=yes | UNII=0YHF6E6NLS | _hasJmol02 = |_hasMultipleCASnumbers = |_hasMultiplePubChemCIDs = |_hasMultipleChEBIs =

| _countSecondIDs= | _countIndexlabels= | _trackListSortletter= |QID = |QID2 = |Verifiedfields=changed |Watchedfields=changed |verifiedrevid=447984130}}

Fentiazac is a thiazole-based nonsteroidal anti-inflammatory drug (NSAID) developed for use in joint and muscular pain. Like most other NSAIDs, it acts through inhibition of prostaglandin synthesis, via non-selective inhibition of both COX-1 and COX-2. First described in 1974, it was synthesized using the Hantzsch thiazole synthesis.

Fentiazac was marketed under the trade-name Norvedan (among others), but its market status is currently unknown and assumed to be discontinued.

See also

• Fenclozic acid